These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9086288)

  • 1. In vivo determination of drug kinetic linearity and individual organ elimination by the accelerated infusion technique.
    Li J; Dobson GL; Marietta MP; Rhodes GR; Hidalgo IJ
    J Pharmacol Toxicol Methods; 1997 Feb; 37(1):47-53. PubMed ID: 9086288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel simultaneous modeling approach to estimate linearity of pharmacokinetic parameters, including saturation of intestinal efflux, in the rat.
    Williams JA; Sahasrabudhe V; Walton J; Zhu T; Hudson G; Koup JR
    J Pharmacol Toxicol Methods; 2005; 52(3):307-13. PubMed ID: 15979348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction.
    Letendre L; Scott M; Dobson G; Hidalgo I; Aungst B
    Pharm Res; 2004 Aug; 21(8):1457-62. PubMed ID: 15359582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the use of accelerated infusions for the determination of pharmacokinetic linearity.
    Ward KW; Griffiths R; Levy MA; Smith BR
    J Pharmacol Exp Ther; 2000 May; 293(2):468-79. PubMed ID: 10773017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats.
    Matsuda Y; Konno Y; Satsukawa M; Kobayashi T; Takimoto Y; Morisaki K; Yamashita S
    Drug Metab Dispos; 2012 Dec; 40(12):2231-8. PubMed ID: 22930277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of D-propranolol following oral, intra-arterial and intraportal administration: contrasting effects of oral glucose pretreatment.
    Chow HH; Lalka D
    Biopharm Drug Dispos; 1993 Apr; 14(3):217-31. PubMed ID: 8490110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the routes of continuous intrahepatic infusion of 5-fluorouracil on its pharmacokinetics.
    Didolkar MS; Jackson AJ; Covell DG; Walker AP; Eddington ND
    J Surg Oncol; 1989 Jul; 41(3):187-93. PubMed ID: 2747244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal first-pass effect of YJA-20379-8, a new reversible proton pump inhibitor, in rats.
    Kim J; Kim EJ; Han KS; Chang MS; Lee MG
    J Pharm Pharmacol; 1999 Sep; 51(9):1031-6. PubMed ID: 10528986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the first-pass metabolism of ebastine in rats.
    Fujii T; Matsumoto S; Hatoyama T; Miyazaki H
    Arzneimittelforschung; 1997 Aug; 47(8):949-53. PubMed ID: 9296281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal absorption and presystemic elimination of the prokinetic agent, EM574, in the rabbit.
    Gan G; Cartier LL; Huang Y; Yang Z; Sawchuk RJ
    J Pharm Sci; 2002 Jan; 91(1):217-28. PubMed ID: 11782911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, protein binding, pharmacokinetics and excretion of the anti-ischemic and anti-hypertensive arylpiperazine derivative CDRI-93/478 in rats.
    Lal J; Gupta RC
    Arzneimittelforschung; 2008; 58(2):62-70. PubMed ID: 18412019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent pharmacokinetics of midazolam in rats: influence of hepatic first-pass metabolism.
    Li R; Wang Q; Liu Z; Xie L; Diao Z; Peng Y; Wang G; Sun J
    Xenobiotica; 2023 Mar; 53(3):184-192. PubMed ID: 37042732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-pass metabolism of 5-fluorouracil in rats.
    Yuasa H; Gu J; Hayashi Y; Watanabe J
    J Pharm Pharmacol; 1998 Sep; 50(9):1019-25. PubMed ID: 9811163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
    Kim SH; Lee MG
    Life Sci; 2002 Feb; 70(11):1299-315. PubMed ID: 11883708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral absorption of FK506 in rats.
    Kagayama A; Tanimoto S; Fujisaki J; Kaibara A; Ohara K; Iwasaki K; Hirano Y; Hata T
    Pharm Res; 1993 Oct; 10(10):1446-50. PubMed ID: 7505939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells-correlation with in vivo absorption predicted in humans.
    Li C; Liu T; Broske L; Brisson JM; Uss AS; Njoroge FG; Morrison RA; Cheng KC
    Biochem Pharmacol; 2008 Dec; 76(12):1757-64. PubMed ID: 18835257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist.
    Imawaka H; Sugiyama Y
    J Pharmacol Exp Ther; 1998 Mar; 284(3):949-57. PubMed ID: 9495854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats.
    Wang X; Zheng M; Liu J; Huang Z; Bai Y; Ren Z; Wang Z; Tian Y; Qiao Z; Liu W; Feng F
    J Ethnopharmacol; 2017 Sep; 209():175-183. PubMed ID: 28755970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.